Apollomics Past Earnings Performance
Past criteria checks 0/6
Apollomics's earnings have been declining at an average annual rate of -22.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 70.5% per year.
Key information
-22.2%
Earnings growth rate
-16.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 70.5% |
| Return on equity | -274.5% |
| Net Margin | -2,718.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Apollomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -57 | 21 | 35 |
| 31 Mar 24 | 1 | -115 | 21 | 34 |
| 31 Dec 23 | 1 | -173 | 21 | 34 |
| 30 Sep 23 | 1 | -280 | 18 | 34 |
| 30 Jun 23 | 1 | -388 | 15 | 34 |
| 31 Mar 23 | 1 | -314 | 12 | 35 |
| 31 Dec 22 | 0 | -241 | 10 | 35 |
| 30 Sep 22 | 0 | -136 | 12 | 35 |
| 30 Jun 22 | 1 | -32 | 13 | 35 |
| 31 Mar 22 | 1 | -63 | 14 | 35 |
| 31 Dec 21 | 0 | -95 | 15 | 36 |
| 31 Dec 20 | 2 | -75 | 11 | 31 |
Quality Earnings: APLM is currently unprofitable.
Growing Profit Margin: APLM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APLM is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare APLM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APLM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: APLM has a negative Return on Equity (-274.49%), as it is currently unprofitable.